Structural Insight Into Dfmo Resistant Ornithine Decarboxylase from Entamoeba Histolytica: An Inkling to Adaptive Evolution.
Preeti, P., Tapas, S., Kumar, P., Tomar, S.(2013) PLoS One 8: 53397
- PubMed: 23326423 
- DOI: https://doi.org/10.1371/journal.pone.0053397
- Primary Citation of Related Structures:  
4AIB - PubMed Abstract: 
Polyamine biosynthetic pathway is a validated therapeutic target for large number of infectious diseases including cancer, giardiasis and African sleeping sickness, etc. α-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis. The enzyme ODC of E. histolytica (EhODC) has been reported to exhibit resistance towards DFMO.
Organizational Affiliation: 
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand, India.